Table 1:
All-cause mortality and cefiderocol non-susceptibility among carbapenem-resistant pathogens
| Acinetobacter | Klebsiella | Pseudomonas | Stenotrophomonas | |
|---|---|---|---|---|
| CREDIBLE-CR trial1 | ||||
| All-cause mortality* | 49% (19/39) | 21% (6/28) | 18% (2/11) | 67% (2/3) |
| Detected resistance† | 3% (1/36) | 0% (0/27) | 0% (0/12) | 0% (0/5) |
| SIDERO-CR study5 | ||||
| Detected resistance | 10% (38/368) | 2% (12/720) | 1% (2/262) | 0% (0/217) |
| GA, USA, surveillance | ||||
| Detected resistance | 8% (9/108) | 6% (5/89) | 0% (0/69) | 0% (0/29) |
| Heteroresistance | 59% (64/108) | 30% (27/89) | 9% (6/69) | 48% (14/29) |
All-cause mortality data are from the CREDIBLE-CR trial.1 Detected resistance data (minimum inhibitory concentration >4 μg/mL) are from the CREDIBLE-CR trial1 or SIDERO-CR study,5 or were generated by disk diffusion assay on carbapenem-resistant isolates from GA, USA, according to Clinical and Laboratory Standards Institute guidance. Heteroresistance data were established by population analysis profile to identify minority resistant subpopulations within an isolate.
All-cause mortality data for Klebsiella, Pseudomonas, and Stenotrophomonas spp are for patients who did not have Acinetobacter spp coinfection.
Data not available for all isolates in the CREDIBLE-CR trial.